Latest & greatest articles for clindamycin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on clindamycin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on clindamycin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for clindamycin

1. One-dose antibiotic prophylaxis against wound infection after appendicectomy: a randomized trial of clindamycin, cefazolin sodium and a placebo. (PubMed)

One-dose antibiotic prophylaxis against wound infection after appendicectomy: a randomized trial of clindamycin, cefazolin sodium and a placebo. Two hundred and fifty patients were admitted to a prospective randomized trial of single dosage prophylaxis against wound infection after appendicectomy. There were 12 exclusions, 72 patients received placebo, 81 received 600 mg i.m. clindamycin phosphate and 85 received 1 1 g i.m. cefazolin sodium, the agent being given in the anaesthetic room (...) . Clindamycin produced a significant reduction in the overall rate of wound infection from 33 per cent in the controls to 17 per cent. In cases with a gangrenous or perforated appendix the infection rate in controls was 78 per cent; this was reduced to 44 per cent by a single dose of clindamycin. Cefazolin significantly reduced the number of aerobic organisms isolated from wound infections, but did not significantly reduce the incidence of wound infection. We conclude that anaerobic organisms are more

1979 British Journal of Surgery

2. Adjunctive clindamycin for cellulitis: a clinical trial comparing flucloxacillin with or without clindamycin for the treatment of limb cellulitis. (PubMed)

Adjunctive clindamycin for cellulitis: a clinical trial comparing flucloxacillin with or without clindamycin for the treatment of limb cellulitis. To compare flucloxacillin with clindamycin to flucloxacillin alone for the treatment of limb cellulitis.Parallel, double-blinded, randomised controlled trial.Emergency department attendances and general practice referrals within 20 hospitals in England.Flucloxacillin, at a minimum of 500 mg 4 times per day for 5 days, with clindamycin 300 mg 4 times (...) of increased side effects.410 patients were included in the trial. No significant difference was seen in improvement at day 5 for flucloxacillin with clindamycin (136/156, 87%) versus flucloxacillin alone (140/172, 81%)-OR 1.55 (95% CI 0.81 to 3.01), p=0.174. There was a significant difference in the number of patients with diarrhoea at day 5 in the flucloxacillin with clindamycin allocation (34/160, 22%) versus flucloxacillin alone (16/176, 9%)-OR 2.7 (95% CI 1.41 to 5.07), p=0.002

Full Text available with Trip Pro

2017 BMJ open

3. Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial. (PubMed)

Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial. Preterm delivery during pregnancy (<37 weeks' gestation) is a leading cause of perinatal mortality and morbidity. Treating bacterial vaginosis during pregnancy can reduce poor outcomes, such as preterm birth. We aimed to investigate whether treatment of bacterial vaginosis decreases late miscarriages or spontaneous very preterm birth.PREMEVA was a double-blind randomised (...) controlled trial done in 40 French centres. Women aged 18 years or older with bacterial vaginosis and low-risk pregnancy were eligible for inclusion and were randomly assigned (2:1) to three parallel groups: single-course or triple-course 300 mg clindamycin twice-daily for 4 days, or placebo. Women with high-risk pregnancy outcomes were eligible for inclusion in a high-risk subtrial and were randomly assigned (1:1) to either single-course or triple-course clindamycin. The primary outcome was a composite

2018 Lancet

4. Clindamycin

Clindamycin Top results for clindamycin - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for clindamycin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

5. Clindamycin phosphate 2% vaginal cream (Clindesse) for the treatment of bacterial vaginosis

Clindamycin phosphate 2% vaginal cream (Clindesse) for the treatment of bacterial vaginosis Clindamycin phosphate 2% vaginal cream (Clindesse) for the treatment of bacterial vaginosis | Therapeutics Initiative Independent Healthcare Evidence > > Clindamycin phosphate 2% vaginal cream (Clindesse) for the treatment of bacterial vaginosis Introduction Pharmaceutical Services Division (PSD) requested a systematic review of Clindesse for the treatment of non-pregnant women ≥ 18 years of age (...) with bacterial vaginosis. Drug Clindesse is a semi-solid white cream containing 2% clindamycin phosphate, which is a water-soluble ester of the semi-synthetic antibiotic produced by a 7 (S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic, lincomycea. The recommended dose is a single intravaginal administration on one day. Disease Bacterial vaginosis is a common vaginal infection caused by an imbalance in the vaginal flora. In bacterial vaginosis there is suppression of lactobacilli

2010 Therapeutics Letter

6. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. (PubMed)

Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. Skin and skin-structure infections are common in ambulatory settings. However, the efficacy of various antibiotic regimens in the era of community-acquired methicillin-resistant Staphylococcus aureus (MRSA) is unclear.We enrolled outpatients with uncomplicated skin infections who had cellulitis, abscesses larger than 5 cm in diameter (smaller for younger children), or both. Patients were enrolled at four study (...) sites. All abscesses underwent incision and drainage. Patients were randomly assigned in a 1:1 ratio to receive either clindamycin or trimethoprim-sulfamethoxazole (TMP-SMX) for 10 days. Patients and investigators were unaware of the treatment assignments and microbiologic test results. The primary outcome was clinical cure 7 to 10 days after the end of treatment.A total of 524 patients were enrolled (264 in the clindamycin group and 260 in the TMP-SMX group), including 155 children (29.6%). One

Full Text available with Trip Pro

2015 NEJM

7. There Is No Difference In The Rates Of Third Molar Post-Operative Inflammatory Complications Between Patients With 600mg Clindamycin, and Patients Without Antibiotics

There Is No Difference In The Rates Of Third Molar Post-Operative Inflammatory Complications Between Patients With 600mg Clindamycin, and Patients Without Antibiotics UTCAT2447, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title There Is No Difference In The Rates Of Third Molar Post-Operative Inflammatory Complications Between Patients With 600mg Clindamycin, and Patients Without Antibiotics Clinical Question (...) In a patient undergoing a third molar extraction, will a clindamycin prophylaxis prevent postoperative inflammatory complications compared to no postoperative antibiotics? Clinical Bottom Line There is no difference in the rates of third molar post-operative inflammatory complications between patients with clindamycin, and patients without antibiotics. For immunocompetent patients undergoing third molar extractions, there is no apparent reason to provide any clindamycin antibiotic intervention

2013 UTHSCSA Dental School CAT Library

8. [Treatment of pregnant women with asymptomatic bacterial vaginosis with clindamycin]

[Treatment of pregnant women with asymptomatic bacterial vaginosis with clindamycin] Klindamycin til gravide med asymptomatisk bakteriell vaginose [Treatment of pregnant women with asymptomatic bacterial vaginosis with clindamycin] Klindamycin til gravide med asymptomatisk bakteriell vaginose [Treatment of pregnant women with asymptomatic bacterial vaginosis with clindamycin] Myrhaug HT, Brurberg KG, Kirkehei I, Reinar LM Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Myrhaug HT, Brurberg KG, Kirkehei I, Reinar LM. Klindamycin til gravide med asymptomatisk bakteriell vaginose. [Treatment of pregnant women with asymptomatic bacterial vaginosis with clindamycin] Oslo: Norwegian Knowledge Centre for the Health Services (NOKC). Report from NOKC nr 11 - 2010. 2010 Authors' conclusions Clindamycin treatment of pregnant women

2010 Health Technology Assessment (HTA) Database.

9. Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris

Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies (...) Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details

2014 Clinical Trials

10. Adjunctive Clindamycin for Cellulitis: Clinical Trial Comparing Flucloxacillin With or Without Clindamycin for the Treatment of Limb Cellulitis (C4C Trial).

Adjunctive Clindamycin for Cellulitis: Clinical Trial Comparing Flucloxacillin With or Without Clindamycin for the Treatment of Limb Cellulitis (C4C Trial). Adjunctive Clindamycin for Cellulitis: C4C Trial. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Adjunctive Clindamycin for Cellulitis: C4C Trial. (C4C) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01876628 Recruitment Status : Unknown Verified November 2015 by University Hospitals Bristol NHS Foundation Trust. Recruitment status

2013 Clinical Trials

11. Efficacy of oral metronidazole with vaginal clindamycin or vaginal probiotic for bacterial vaginosis: randomised placebo-controlled double-blind trial. (PubMed)

Efficacy of oral metronidazole with vaginal clindamycin or vaginal probiotic for bacterial vaginosis: randomised placebo-controlled double-blind trial. To determine if oral metronidazole (MTZ-400 mg bid) with 2% vaginal clindamycin-cream (Clind) or a Lactobacillus acidophilus vaginal-probiotic containing oestriol (Prob) reduces 6-month bacterial vaginosis (BV) recurrence.Double-blind placebo-controlled parallel-group single-site study with balanced randomization (1:1:1) conducted at Melbourne (...)  = 0.70-1.70) and 1.03(95% CI = 0.65-1.63), respectively. No serious adverse events occurred.Combining the recommended first line therapies of oral metronidazole and vaginal clindamycin, or oral metronidazole with an extended-course of a commercially available vaginal-L.acidophilus probiotic, does not reduce BV recurrence.ANZCTR.org.au ACTRN12607000350426.

Full Text available with Trip Pro

2012 PloS one

12. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: Assessment of efficacy and safety in 2813 patients (PubMed)

An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: Assessment of efficacy and safety in 2813 patients We sought to evaluate efficacy, safety, and tolerability of a combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% (clindamycin-BPO 2.5%) aqueous gel in moderate to severe acne vulgaris.A total of 2813 patients, aged 12 years or older, were randomized to receive clindamycin-BPO (...) with clindamycin-BPO 2.5% as early as week 2. No substantive differences were seen in cutaneous tolerability among treatment groups and less than 1% of patients discontinued treatment because of adverse events.Data from controlled studies may differ from clinical practice.Clindamycin-BPO 2.5% provides statistically significant greater efficacy than individual active ingredients and vehicle with a highly favorable safety and tolerability profile.

2008 EvidenceUpdates

13. Clinical outcomes in patients hospitalized with cellulitis treated with oral clindamycin and trimethoprim/sulfamethoxazole: the role of weight-based dosing. (PubMed)

Clinical outcomes in patients hospitalized with cellulitis treated with oral clindamycin and trimethoprim/sulfamethoxazole: the role of weight-based dosing. Trimethoprim/sulfamethoxazole (TMP/SMX) and clindamycin are frequently prescribed to treat cellulitis. The primary objective was to determine if weight-based dosing of these antibiotics is associated with better outcomes in cellulitis. The secondary objective was to assess variables associated with clinical failure among hospitalized (...) patients with cellulitis with or without cutaneous abscess.This multi-center retrospective cohort study was conducted from January 1, 2010 to September 4, 2014. Adult patients admitted for cellulitis who received a minimum of seven days of therapy and discharged on oral clindamycin or TMP/SMX were included. Binary univariate and multivariate logistic regression analyses were performed to identify risk factors for clinical failure, including the impact of dose adequacy of clindamycin and TMP/SMX

2017 Journal of Infection

14. Long-term clinical safety of Clindamycin and Rifampicin combination for the treatment of Hidradenitis suppurativa: a critically appraised topic. (PubMed)

Long-term clinical safety of Clindamycin and Rifampicin combination for the treatment of Hidradenitis suppurativa: a critically appraised topic. Can therapy with clindamycin and rifampicin be safely continued long term beyond the recommended 10-week course?Clindamycin and rifampicin are used in combination to treat hidradenitis suppurativa (HS). There is no data on the efficacy and safety of clindamycin/rifampicin combination therapy for HS beyond 10 weeks.We identified the following major (...) concerns that still lack a proper evidenced-based analysis: for rifampicin, drug-induced liver injury, interstitial nephritis, drug interaction and hepatic p450 3A4 enzyme induction; for clindamycin, the concern was community-acquired Clostridium difficile infection (CA-CDI); and experience with long-term treatment. Data sources were used as appropriate to answer the question. Systematic searches were used to assess the risk of CA-CDI and experience with long-term treatment with clindamycin.The risk

2018 British Journal of Dermatology

15. Moxifloxacin versus Clindamycin/Ceftriaxone in the management of odontogenic maxillofacial infectious processes: A preliminary, intrahospital, controlled clinical trial. (PubMed)

Moxifloxacin versus Clindamycin/Ceftriaxone in the management of odontogenic maxillofacial infectious processes: A preliminary, intrahospital, controlled clinical trial. The aim of this study was to compare the days of hospitalization length between patients treated with Moxifloxacin with that of patients treated with a Clindamycin/Ceftriaxone combination and additionally, to isolate and identify the oral pathogens involved in orofacial odontogenic infections.A pilot-controlled-clinical-trial (...) was carried out on hospitalized patients with cervicofacial odontogenic abscesses or cellulitis, who were randomly asigned to two study groups: 1) patients who received Moxifloxacin, and 2) patients receiving Clindamycin/Ceftriaxone combination. Infiltrate samples were collected through transdermic or transmucosal punction and later cultured on a media specific for aerobic and anaerobic microorganisms. Mean hospitalization duration in days until hospital discharge and susceptibility assessment in rates

Full Text available with Trip Pro

2015 Journal of clinical and experimental dentistry

16. [Clinical efficacy of fluconazole, tinidazole and clindamycin vs fluconazole, tinidazole and azithromycin in the treatment of mixed cervical-vaginal infections, included those caused by Mycoplasma and Chlamydia trachomatis].

[Clinical efficacy of fluconazole, tinidazole and clindamycin vs fluconazole, tinidazole and azithromycin in the treatment of mixed cervical-vaginal infections, included those caused by Mycoplasma and Chlamydia trachomatis]. In the United States 19 million people acquire a sexually transmitted disease every year. Sexually transmitted diseases impact in gynecological terms because they may cause sterility, infertility and ectopic pregnancy.To compare the effectiveness of two combinations (...) of three oral antimicrobial drugs in the treatment of mixed cervical-vaginal infections, included those caused by Mycoplasma and Chlamydia trachomatis.Aclinical, random, comparative, double-blind study included 50 patients assisting to infectology consult with diagnosis of mixed cervical-vaginal infection. Patients were divided into two groups: Group A (n = 25): fluconazole 37.5 mg, tinidazole 500 mg and azithromycin 250 mg; group B (n = 25): fluconazole 37.5 mg, tinidazole 500 mg and clindamycin 312.5

2013 Ginecología y obstetricia de México

17. Randomized controlled trial of cephalexin versus clindamycin for uncomplicated pediatric skin infections (PubMed)

Randomized controlled trial of cephalexin versus clindamycin for uncomplicated pediatric skin infections To compare clindamycin and cephalexin for treatment of uncomplicated skin and soft tissue infections (SSTIs) caused predominantly by community-associated (CA) methicillin-resistant Staphylococcus aureus (MRSA). We hypothesized that clindamycin would be superior to cephalexin (an antibiotic without MRSA activity) for treatment of these infections.Patients aged 6 months to 18 years (...) with uncomplicated SSTIs not requiring hospitalization were enrolled September 2006 through May 2009. Eligible patients were randomly assigned to 7 days of cephalexin or clindamycin; primary and secondary outcomes were clinical improvement at 48 to 72 hours and resolution at 7 days. Cultures were obtained and tested for antimicrobial susceptibilities, pulsed-field gel electrophoresis type, and Panton-Valentine leukocidin status.Of 200 enrolled patients, 69% had MRSA cultured from wounds. Most MRSA were USA300

Full Text available with Trip Pro

2011 EvidenceUpdates

18. Comparison Between Oral Clindamycin Vs Metronidazole for the Treatment of Abnormal Vaginal Flora in High Risk Pregnancies

Comparison Between Oral Clindamycin Vs Metronidazole for the Treatment of Abnormal Vaginal Flora in High Risk Pregnancies Comparison Between Oral Clindamycin Vs Metronidazole for the Treatment of Abnormal Vaginal Flora in High Risk Pregnancies - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Comparison Between Oral Clindamycin Vs Metronidazole for the Treatment of Abnormal Vaginal Flora in High Risk Pregnancies The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details

2012 Clinical Trials

19. Assessing the Necessity of Prescribing Antibiotics (Clavulin or Clindamycin Versus Placebo) Post-peritonsillar Abscess Drainage

Assessing the Necessity of Prescribing Antibiotics (Clavulin or Clindamycin Versus Placebo) Post-peritonsillar Abscess Drainage Assessing the Necessity of Prescribing Antibiotics (Clavulin or Clindamycin Versus Placebo) Post-peritonsillar Abscess Drainage - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. Assessing the Necessity of Prescribing Antibiotics (Clavulin or Clindamycin Versus Placebo) Post-peritonsillar Abscess Drainage (PTA) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01715610 Recruitment Status

2012 Clinical Trials

20. Microbiological analysis of a prospective, randomized, double-blind trial comparing moxifloxacin and clindamycin in the treatment of odontogenic infiltrates and abscesses. (PubMed)

Microbiological analysis of a prospective, randomized, double-blind trial comparing moxifloxacin and clindamycin in the treatment of odontogenic infiltrates and abscesses. The objective of this study was to identify the oral pathogens found in odontogenic infections, to determine their susceptibilities to amoxicillin-clavulanic acid (AMC), clindamycin (CLI), doxycycline (DOX), levofloxacin (LVX), moxifloxacin (MXF), and penicillin (PEN), and to search for associations between specific pathogens

Full Text available with Trip Pro

2012 Antimicrobial agents and chemotherapy